Welcome to LookChem.com Sign In|Join Free
  • or
2-Chloro-N,N-dimethylacetamide, also known as N,N-dimethylchloroacetamide, is an N,M-dialkyl amide that serves as an organic catalyst in various chemical reactions. It is characterized by the presence of a chloro group attached to the carbonyl carbon, with two methyl groups attached to the nitrogen atom. This unique structure endows it with properties that make it a valuable component in the synthesis of various compounds.

2675-89-0

Post Buying Request

2675-89-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

2675-89-0 Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-N,N-dimethylacetamide is used as an organic catalyst for the preparation of phosphorylated thiosemicarbazide, which is an important intermediate in the synthesis of pharmaceutical compounds. Its catalytic properties facilitate the reaction process, leading to the efficient production of the desired product.
Used in Chemical Synthesis:
In the field of chemical synthesis, 2-Chloro-N,N-dimethylacetamide is utilized in the synthesis of (S)-carbinoxamine, a compound with potential applications in various industries. The use of this amide as a catalyst aids in the formation of the desired product, showcasing its versatility in different chemical processes.

Check Digit Verification of cas no

The CAS Registry Mumber 2675-89-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,6,7 and 5 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 2675-89:
(6*2)+(5*6)+(4*7)+(3*5)+(2*8)+(1*9)=110
110 % 10 = 0
So 2675-89-0 is a valid CAS Registry Number.
InChI:InChI=1/C4H8ClNO/c1-6(2)4(7)3-5/h3H2,1-2H3

2675-89-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (H50229)  2-Chloro-N,N-dimethylacetamide, 97%   

  • 2675-89-0

  • 250mg

  • 814.0CNY

  • Detail
  • Alfa Aesar

  • (H50229)  2-Chloro-N,N-dimethylacetamide, 97%   

  • 2675-89-0

  • 1g

  • 2933.0CNY

  • Detail

2675-89-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-Chloro-N,N-dimethylacetamide

1.2 Other means of identification

Product number -
Other names CHLOROACETYLDIMETHYLAMINE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:2675-89-0 SDS

2675-89-0Synthetic route

dimethyl amine
124-40-3

dimethyl amine

chloroacetyl chloride
79-04-9

chloroacetyl chloride

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

Conditions
ConditionsYield
With sodium hydrogencarbonate In toluene at -2 - 5℃; for 1h; Reagent/catalyst; Solvent; Temperature;93.1%
With triethylamine In dichloromethane at -5 - 20℃; for 13h; Inert atmosphere;93.09%
In diethyl ether at 20℃; Cooling;81%
N,N-dimethylammonium chloride
506-59-2

N,N-dimethylammonium chloride

chloroacetyl chloride
79-04-9

chloroacetyl chloride

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

Conditions
ConditionsYield
With triethylamine In dichloromethane at 15℃;77%
With triethylamine In dichloromethane at 0℃; for 3h;62%
With sodium hydroxide In 1,2-dichloro-ethane at -5℃; for 0.5h;33%
diethyl 2-amino-6-[(hydroxycarbamoyl)-methyl]-azulene-1,3-dicarboxylate sodium
227945-00-8

diethyl 2-amino-6-[(hydroxycarbamoyl)-methyl]-azulene-1,3-dicarboxylate sodium

A

diethyl 2-amino-6-[(2-oxo-2-N,N-dimethylamino-ethoxycarbamoyl)-methyl]-azulene-1,3-dicarboxylate

diethyl 2-amino-6-[(2-oxo-2-N,N-dimethylamino-ethoxycarbamoyl)-methyl]-azulene-1,3-dicarboxylate

B

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

Conditions
ConditionsYield
A 27%
B n/a
Ketene
463-51-4

Ketene

diethyl ether
60-29-7

diethyl ether

dimethylchloroamine
1585-74-6

dimethylchloroamine

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

Conditions
ConditionsYield
at -60℃;
Ketene
463-51-4

Ketene

dimethylchloroamine
1585-74-6

dimethylchloroamine

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

Conditions
ConditionsYield
With diethyl ether at -60℃;
Chloroacetic anhydride
541-88-8

Chloroacetic anhydride

N,N-Dimethylcarbamoyl chloride
79-44-7

N,N-Dimethylcarbamoyl chloride

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

sodium monochloroacetic acid
3926-62-3

sodium monochloroacetic acid

N,N-Dimethylcarbamoyl chloride
79-44-7

N,N-Dimethylcarbamoyl chloride

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

bis-(dimethylamino)methane
51-80-9

bis-(dimethylamino)methane

Chloroacetic anhydride
541-88-8

Chloroacetic anhydride

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

Conditions
ConditionsYield
In chloroform
Dimethyl-(6-methyl-2-oxo-2λ5-[1,3,2]oxathiaphosphinan-2-yl)-amine
139575-17-0

Dimethyl-(6-methyl-2-oxo-2λ5-[1,3,2]oxathiaphosphinan-2-yl)-amine

A

2-Chloro-6-methyl-[1,3,2]oxathiaphosphinane 2-oxide
139575-18-1

2-Chloro-6-methyl-[1,3,2]oxathiaphosphinane 2-oxide

B

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

Conditions
ConditionsYield
With chloroacetyl chloride Heating;
Dimethyl-(6-methyl-2-oxo-2λ5-[1,3,2]oxathiaphosphinan-2-yl)-amine
139575-17-0

Dimethyl-(6-methyl-2-oxo-2λ5-[1,3,2]oxathiaphosphinan-2-yl)-amine

chloroacetyl chloride
79-04-9

chloroacetyl chloride

A

2-Chloro-6-methyl-[1,3,2]oxathiaphosphinane 2-oxide
139575-18-1

2-Chloro-6-methyl-[1,3,2]oxathiaphosphinane 2-oxide

B

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

Conditions
ConditionsYield
Heating;
dimethyl amine
124-40-3

dimethyl amine

chloroacetic acid
79-11-8

chloroacetic acid

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

Conditions
ConditionsYield
Stage #1: chloroacetic acid With dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 0.5h;
Stage #2: dimethyl amine With dmap In dichloromethane at 20℃;
chloroacetyl chloride
79-04-9

chloroacetyl chloride

methylamine
74-89-5

methylamine

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

Conditions
ConditionsYield
In tetrahydrofuran; dichloromethane at -40℃; for 1h;
N,N-dimethyl acetamide
127-19-5

N,N-dimethyl acetamide

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

Conditions
ConditionsYield
With copper dichloride at 150℃; for 24h; Inert atmosphere;
N,N-dimethyl acetamide
127-19-5

N,N-dimethyl acetamide

A

4-chloro-N,N-dimethyl-3-oxobutanamide

4-chloro-N,N-dimethyl-3-oxobutanamide

B

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

Conditions
ConditionsYield
Stage #1: N,N-dimethyl acetamide With n-butyllithium; diisopropylamine In tetrahydrofuran; hexane at -78℃; for 0.5h; Inert atmosphere;
Stage #2: With methyl chlorosulfate In tetrahydrofuran; hexane at -78℃; for 0.5h; Inert atmosphere; Overall yield = 99 %; Overall yield = 87 mg;
1-benzyloxy-5-(4-methoxy-benzyloxy)-9-(tetrahydro-pyran-2-yloxy)-non-7-en-4-ol
934977-35-2

1-benzyloxy-5-(4-methoxy-benzyloxy)-9-(tetrahydro-pyran-2-yloxy)-non-7-en-4-ol

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

2-[1-(3-benzyloxy-propyl)-2-(4-methoxy-benzyloxy)-6-(tetrahydro-pyran-2-yloxy)-hex-4-enyloxy]-N,N-dimethyl-acetamide
934977-36-3

2-[1-(3-benzyloxy-propyl)-2-(4-methoxy-benzyloxy)-6-(tetrahydro-pyran-2-yloxy)-hex-4-enyloxy]-N,N-dimethyl-acetamide

Conditions
ConditionsYield
Stage #1: 1-benzyloxy-5-(4-methoxy-benzyloxy)-9-(tetrahydro-pyran-2-yloxy)-non-7-en-4-ol With sodium hydride In tetrahydrofuran at 0℃; for 0.166667h;
Stage #2: 2-chloro-N,N-dimethylacetamide In tetrahydrofuran at 20℃; for 4h;
100%
1,3-dihydro-1-(1-tert-butyloxycarbonylpiperidin-4-yl)-2H-benzimidazol-2-one
87120-81-8

1,3-dihydro-1-(1-tert-butyloxycarbonylpiperidin-4-yl)-2H-benzimidazol-2-one

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

4-(3-dimethylcarbamoylmethyl-2-oxo-2,3-dihydro-benzimidazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester
928632-88-6

4-(3-dimethylcarbamoylmethyl-2-oxo-2,3-dihydro-benzimidazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester

Conditions
ConditionsYield
With sodium hydride In N,N-dimethyl-formamide100%
(4S)-3-oxo-8-[2-(8-tert-butoxycarbonyl-5,6,7,8-tetrahydroimidazo[1,2-a]-pyrimidin-2-yl)ethoxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepin-4-acetic acid
1152636-93-5

(4S)-3-oxo-8-[2-(8-tert-butoxycarbonyl-5,6,7,8-tetrahydroimidazo[1,2-a]-pyrimidin-2-yl)ethoxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepin-4-acetic acid

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

(N,N-dimethylaminocarbonyl)methyl (4S)-3-oxo-8-[2-(8-tert-butoxycarbonyt-5,6,7,8-tetrahydroimidazo[1,2-a]pyrimidin-2-yl)ethoxy]-2-(2,2,2-trifluooroethyl)-2,3,4,5-tetrahydro-1H-2-benzazep in-4-acetate
1152636-97-9

(N,N-dimethylaminocarbonyl)methyl (4S)-3-oxo-8-[2-(8-tert-butoxycarbonyt-5,6,7,8-tetrahydroimidazo[1,2-a]pyrimidin-2-yl)ethoxy]-2-(2,2,2-trifluooroethyl)-2,3,4,5-tetrahydro-1H-2-benzazep in-4-acetate

Conditions
ConditionsYield
With potassium carbonate In water; N,N-dimethyl-formamide at 20℃; Inert atmosphere;100%
With potassium carbonate In N,N-dimethyl-formamide at 20℃; for 8h; Inert atmosphere;
(6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)-acetic acid
1187450-51-6

(6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)-acetic acid

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

[2-(dimethylamino)-2-oxoethyl] (6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]-aminomethyl} pyridin-2-ylamino)acetate
1273387-10-2

[2-(dimethylamino)-2-oxoethyl] (6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]-aminomethyl} pyridin-2-ylamino)acetate

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 20℃; for 4h;100%
methyl 6-(2,6-difluoro-4-hydroxyphenyl)-5-fluoropyridine-2-carboxylate
1355011-30-1

methyl 6-(2,6-difluoro-4-hydroxyphenyl)-5-fluoropyridine-2-carboxylate

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

methyl 6-(4-(2-(dimethylamino)-2-oxoethoxy)-2,6-difluorophenyl)-5-fluoropicolinate
1395986-73-8

methyl 6-(4-(2-(dimethylamino)-2-oxoethoxy)-2,6-difluorophenyl)-5-fluoropicolinate

Conditions
ConditionsYield
Stage #1: methyl 6-(2,6-difluoro-4-hydroxyphenyl)-5-fluoropyridine-2-carboxylate With sodium hydride In N,N-dimethyl-formamide; mineral oil at 20℃; for 0.5h;
Stage #2: 2-chloro-N,N-dimethylacetamide In N,N-dimethyl-formamide; mineral oil at 20℃;
100%
C17H24O5
947619-71-8

C17H24O5

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

C21H31NO6
947619-72-9

C21H31NO6

Conditions
ConditionsYield
With sodium hydride In tetrahydrofuran at 20℃; for 0.5h;99%
3-[(R)-1-(4-bromo-phenyl)-1-cyclopropyl-ethyl]-5-(1H-pyrazol-4-yl)-[1,2,4]oxadiazole
1360552-35-7

3-[(R)-1-(4-bromo-phenyl)-1-cyclopropyl-ethyl]-5-(1H-pyrazol-4-yl)-[1,2,4]oxadiazole

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

2-(4-{3-[(R)-1-(4-bromophenyl)-1-cyclopropylethyl]-[1,2,4]oxadiazol-5-yl}pyrazol-1-yl)-N,N-dimethylacetamide
1360552-37-9

2-(4-{3-[(R)-1-(4-bromophenyl)-1-cyclopropylethyl]-[1,2,4]oxadiazol-5-yl}pyrazol-1-yl)-N,N-dimethylacetamide

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 20℃; Inert atmosphere;99%
tert-butyl (E)-(2S,3S)-2-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-3-[(S)-2-(4-but-2-ynyloxy-phenyl)-1-carboxy-ethylcarbamoyl]-11-(2-heptyl-[1,3]dioxolan-2-yl)-2-hydroxy-undec-4-enoate

tert-butyl (E)-(2S,3S)-2-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-3-[(S)-2-(4-but-2-ynyloxy-phenyl)-1-carboxy-ethylcarbamoyl]-11-(2-heptyl-[1,3]dioxolan-2-yl)-2-hydroxy-undec-4-enoate

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

C51H84N2O11Si

C51H84N2O11Si

Conditions
ConditionsYield
With tetra-(n-butyl)ammonium iodide; N-ethyl-N,N-diisopropylamine In dichloromethane at 50℃; for 12h; Inert atmosphere;99%
(2S,3S)-(+)-1,2-epoxy-3-octanol
96856-99-4

(2S,3S)-(+)-1,2-epoxy-3-octanol

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

C12H23NO3

C12H23NO3

Conditions
ConditionsYield
Stage #1: (2S,3S)-(+)-1,2-epoxy-3-octanol With sodium hydride In tetrahydrofuran; mineral oil at 0℃; for 0.166667h; Inert atmosphere;
Stage #2: 2-chloro-N,N-dimethylacetamide In tetrahydrofuran; mineral oil at 0 - 20℃; for 7h; Inert atmosphere;
98%
C21H26N2O2

C21H26N2O2

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

C25H33N3O3

C25H33N3O3

Conditions
ConditionsYield
Stage #1: C21H26N2O2 With sodium hydride In N,N-dimethyl-formamide; mineral oil at 0 - 20℃; for 0.25h;
Stage #2: 2-chloro-N,N-dimethylacetamide In N,N-dimethyl-formamide; mineral oil for 1h;
98%
2-phenyl-6H-pyrrolo<3,2-e>benzoxazole
169170-98-3

2-phenyl-6H-pyrrolo<3,2-e>benzoxazole

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

8-chloroacetyl-2-phenyl-6H-pyrrolo<3,2-e>benzoxazole

8-chloroacetyl-2-phenyl-6H-pyrrolo<3,2-e>benzoxazole

Conditions
ConditionsYield
With trichlorophosphate In 1,4-dioxane at 80℃; for 1h;97%
(S)-(4-Methylphenyl)phenylmethanol
24218-12-0

(S)-(4-Methylphenyl)phenylmethanol

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

N,N-dimethyl-2-((S)-(4-methylphenyl)(phenyl)methoxy)acetamide

N,N-dimethyl-2-((S)-(4-methylphenyl)(phenyl)methoxy)acetamide

Conditions
ConditionsYield
With sodium hydride In tetrahydrofuran at 25℃; for 4h; enantioselective reaction;97%
With sodium hydride In tetrahydrofuran at 0 - 20℃; for 5h;91%
With sodium hydride In diethyl ether
(R)-1-(4-Methoxy-benzyloxy)-but-3-en-2-ol

(R)-1-(4-Methoxy-benzyloxy)-but-3-en-2-ol

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

C16H23NO4
1214736-95-4

C16H23NO4

Conditions
ConditionsYield
With sodium hydride In N,N-dimethyl-formamide; mineral oil at 0 - 20℃; Inert atmosphere;97%
C25H31N3O3

C25H31N3O3

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

C29H38N4O4

C29H38N4O4

Conditions
ConditionsYield
With potassium carbonate; sodium iodide In N,N-dimethyl-formamide at 40℃; for 4h;97%
isopropenylbenzene
98-83-9

isopropenylbenzene

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

C13H18(2)HNO

C13H18(2)HNO

Conditions
ConditionsYield
With (1-2H)-D-glucose; nicotinamide adenine dinucleotide phosphate; GDH-105 lysate; MPTLFDPIDFGPIHAKNRIVMSPLTRGRADKEAVPAPIMAEYYAQRASAGLIITEATGISREGLGWPFAPGIWSDAQVEAWKPIVAGVHAKGGKIVCQLWHMGRMVHSSVTGTQPVSSSATTAPGEVHTYEGKKPFEQARAIDAADISRILNDYENAARNAIRAGFDGVQIHAANGYLIDEFLRNGTNHRTDEYGGVPENRIRFLKEVTERVIAAIGADRTGVRLSPNGDTQGCIDSAPETVFVPAAKLLQDLGVAWLELREPGPNGTFGKTDQPKLSPQIRKVFLRPLVLNQDYTFEAAQTALAEGKADAIAFGRKFISNPDLPERFARGIALQPDDMKTWYSQGPEGYTDYPSATSGPNN In dimethyl sulfoxide for 24h; pH=9; Reagent/catalyst; Irradiation; Sealed tube; Enzymatic reaction; enantioselective reaction;97%
2-methyl-(S)-benzhydrol
1517-59-5

2-methyl-(S)-benzhydrol

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

N,N-dimethyl-2-(phenyl-o-tolyl-methoxy)-acetamide

N,N-dimethyl-2-(phenyl-o-tolyl-methoxy)-acetamide

Conditions
ConditionsYield
With sodium hydride In tetrahydrofuran at 20℃;96.1%
With sodium hydride In tetrahydrofuran at 25℃; for 4h; Substitution;89%
1'-[(5-chloro-1H-indol-2-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one
1032189-20-0

1'-[(5-chloro-1H-indol-2-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

2-{5-chloro-2-[(5-fluoro-3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)carbonyl]-1H-indol-1-yl}-N,N-dimethylacetamide
1032189-22-2

2-{5-chloro-2-[(5-fluoro-3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)carbonyl]-1H-indol-1-yl}-N,N-dimethylacetamide

Conditions
ConditionsYield
Stage #1: 1'-[(5-chloro-1H-indol-2-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one With sodium hydride In N,N-dimethyl-formamide; mineral oil at 20℃; for 0.333333h;
Stage #2: 2-chloro-N,N-dimethylacetamide In N,N-dimethyl-formamide; mineral oil at 20℃;
96%
C28H38O5
1214737-09-3

C28H38O5

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

C32H45NO6
1214737-10-6

C32H45NO6

Conditions
ConditionsYield
With sodium hydride In N,N-dimethyl-formamide; mineral oil at 0 - 20℃; for 3h; Inert atmosphere;96%
C22H28O4
1309589-62-5

C22H28O4

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

C26H35NO5
1309589-63-6

C26H35NO5

Conditions
ConditionsYield
With sodium hydride In tetrahydrofuran; N,N-dimethyl-formamide at 0 - 20℃; for 15h; Williamson etherification;96%
5-(4-{(R)-1-cyclopropyl-1-[5-(1H-pyrazol-4-yl)-[1,2,4]oxadiazol-3-yl]ethyl}phenyl)pyrimidin-2-ylamine
1360549-37-6

5-(4-{(R)-1-cyclopropyl-1-[5-(1H-pyrazol-4-yl)-[1,2,4]oxadiazol-3-yl]ethyl}phenyl)pyrimidin-2-ylamine

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

2-[4-(3-{(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl}-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl]-N,N-dimethylacetamide
1360550-04-4

2-[4-(3-{(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl}-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl]-N,N-dimethylacetamide

Conditions
ConditionsYield
With 1,8-diazabicyclo[5.4.0]undec-7-ene In N,N-dimethyl-formamide at 48 - 50℃; for 0.5h; Large scale;95.6%
With 1,8-diazabicyclo[5.4.0]undec-7-ene In N,N-dimethyl-formamide at 50℃; for 1h; Inert atmosphere;94.4%
With potassium carbonate In N,N-dimethyl-formamide at 20℃; for 2h;
With potassium carbonate In N,N-dimethyl-formamide at 20℃; for 2h;10 g
25,26-Bis<(ethoxycarbonyl)methoxy>-27,28-dihydroxycalix<4>arene
147087-50-1

25,26-Bis<(ethoxycarbonyl)methoxy>-27,28-dihydroxycalix<4>arene

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

25,26-Bis<(dimethylcarbamoyl)methoxy>-27,28-bis<(ethoxycarbonyl)methoxy>calix<4>arene

25,26-Bis<(dimethylcarbamoyl)methoxy>-27,28-bis<(ethoxycarbonyl)methoxy>calix<4>arene

Conditions
ConditionsYield
With caesium carbonate; sodium iodide In acetonitrile at 60℃;95%
(4R,5R)-7-benzyloxy-5-(4-methoxybenzyloxy)hept-1-en-4-ol
869386-01-6

(4R,5R)-7-benzyloxy-5-(4-methoxybenzyloxy)hept-1-en-4-ol

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

(1'R,1R)-2-{1-[3'-benzyloxy-1'-(4-methoxybenzyloxy)propyl]but-3-enyloxy}-N,N-dimethylacetamide
869385-99-9

(1'R,1R)-2-{1-[3'-benzyloxy-1'-(4-methoxybenzyloxy)propyl]but-3-enyloxy}-N,N-dimethylacetamide

Conditions
ConditionsYield
With sodium hydride In tetrahydrofuran at 20℃; for 3h;95%
(1,4,8,11-tetraazacyclotetradec-1-yl)acetic acid ethyl ester
468743-82-0

(1,4,8,11-tetraazacyclotetradec-1-yl)acetic acid ethyl ester

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

C26H51N7O5
1186313-12-1

C26H51N7O5

Conditions
ConditionsYield
With potassium carbonate In acetonitrile at 30 - 45℃; for 48h;95%
2-chloro-9-cyclohexyl-7,9-dihydro-8H-purin-8-one
1352623-69-8

2-chloro-9-cyclohexyl-7,9-dihydro-8H-purin-8-one

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

2-(2-chloro-9-cyclohexyl-8-oxo-8,9-dihydro-7H-purin-7-yl)-N,N-dimethyl acetamide
1415152-41-8

2-(2-chloro-9-cyclohexyl-8-oxo-8,9-dihydro-7H-purin-7-yl)-N,N-dimethyl acetamide

Conditions
ConditionsYield
Stage #1: 2-chloro-9-cyclohexyl-7,9-dihydro-8H-purin-8-one; 2-chloro-N,N-dimethylacetamide With sodium hydride In N,N-dimethyl-formamide; mineral oil for 3.25h; Cooling with ice;
Stage #2: for 3h;
95%
1-(benzyloxymethyl)-4-(cyanomethyl)-2-methyl-5-nitroindole
1417791-63-9

1-(benzyloxymethyl)-4-(cyanomethyl)-2-methyl-5-nitroindole

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

3-(1-benzyloxymethyl-2-methyl-5-nitro-1H-indol-4-yl)-3-cyano-N,N-dimethylpropionamide

3-(1-benzyloxymethyl-2-methyl-5-nitro-1H-indol-4-yl)-3-cyano-N,N-dimethylpropionamide

Conditions
ConditionsYield
With 1,8-diazabicyclo[5.4.0]undec-7-ene In N,N-dimethyl-formamide at 60℃; for 24h;95%
C18H12O4

C18H12O4

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

(E)-N,N-dimethyl-2-(3-(3-oxo-3-(2-oxo-2H-chromen-3-yl)prop-1-en-1-yl)phenoxy)acetamide

(E)-N,N-dimethyl-2-(3-(3-oxo-3-(2-oxo-2H-chromen-3-yl)prop-1-en-1-yl)phenoxy)acetamide

Conditions
ConditionsYield
With potassium carbonate; sodium iodide In N,N-dimethyl-formamide at 56℃;94.6%
ephedrine
299-42-3

ephedrine

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

(1R,2S)-2-<(β-hydroxy-α-methylphenethyl)methylamino>-N,N-dimethylacetamide
130753-27-4

(1R,2S)-2-<(β-hydroxy-α-methylphenethyl)methylamino>-N,N-dimethylacetamide

Conditions
ConditionsYield
With triethylamine In benzene for 8h; Heating;94%
(1R,2R)-pseudoephedrine
321-97-1

(1R,2R)-pseudoephedrine

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

(1R,2R)-2-<(β-hydroxy-α-methylphenethyl)methylamino>-N,N-dimethylacetamide
139528-26-0

(1R,2R)-2-<(β-hydroxy-α-methylphenethyl)methylamino>-N,N-dimethylacetamide

Conditions
ConditionsYield
With triethylamine In benzene for 8h; Heating;94%
n-Pent-4-enyl alcohol
821-09-0

n-Pent-4-enyl alcohol

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

N,N-dimethyl-2-(pent-4-enyloxy)acetamide
1293379-62-0

N,N-dimethyl-2-(pent-4-enyloxy)acetamide

Conditions
ConditionsYield
Stage #1: n-Pent-4-enyl alcohol With sodium hydride In tetrahydrofuran; mineral oil at 0℃; Williamson ether synthesis;
Stage #2: 2-chloro-N,N-dimethylacetamide In tetrahydrofuran; mineral oil at 0 - 20℃; Williamson ether synthesis;
94%
Stage #1: n-Pent-4-enyl alcohol With sodium hydride In tetrahydrofuran; mineral oil at 0℃; for 1h; Williamson synthesis; Inert atmosphere;
Stage #2: 2-chloro-N,N-dimethylacetamide In tetrahydrofuran; mineral oil at 20℃; for 24h; Inert atmosphere;
94%
4,4'-bis[5-heptafluoropropyl-4-(4-pyridyl)oxazol-2-yl]biphenyl
1346142-23-1

4,4'-bis[5-heptafluoropropyl-4-(4-pyridyl)oxazol-2-yl]biphenyl

2-chloro-N,N-dimethylacetamide
2675-89-0

2-chloro-N,N-dimethylacetamide

C42H32F14N6O4(2+)*2Cl(1-)

C42H32F14N6O4(2+)*2Cl(1-)

Conditions
ConditionsYield
at 110℃; for 48h; Inert atmosphere;94%

2675-89-0Relevant academic research and scientific papers

Studies in sulfur-nitrogen nucleophilicity

Caserio, Marjorie C.,Kim, Jhong K.

, (2018)

As part of a study of nitrogen vs sulfur nucleophiles, the behavior of methylation products from dimethyl-(2-methylthioethyl)amine CH3SCH2CH2N(CH3)2 1 is described. Of the 2 potential products (a sulf

Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells

Shi, Xingpeng,Quan, Yanni,Wang, Yixuan,Wang, Ying,Li, Yanping

supporting information, (2020/12/29)

Pancreatic cancer is a highly malignant tumor, and more effective treatment is urgently needed to lengthen the life of patients. In this paper a class of new 2,6,7-substituted pyrrolo[2,3-d]pyrimidine derivatives of CDK 4/6 inhibitor ribociclib (1) was de

Palladium-Catalyzed β-C(sp3)-H Arylation of Aliphatic Ketones Enabled by a Transient Directing Group

Wang, Yangyang,Wu, Gaorong,Xu, Xiaobo,Pang, Binghan,Liao, Shaowen,Ji, Yafei

, p. 7296 - 7303 (2021/05/29)

The direct arylation of aliphatic ketones has been developed via Pd-catalyzed β-C(sp3)-H bond functionalization with 2-(aminooxy)-N,N-dimethylacetamide as a novel transient directing group (TDG), which showed remarkable directing ability to generate arylated products in moderate to good yields. Furthermore, the reaction can tolerate abundant substrate of ketones and aryl iodides. This study expands the scope of applications for TDGs.

Novel selective ido1 inhibitors with isoxazolo[5,4-d]pyrimidin-4(5h)-one scaffold

?vajger, Urban,Bratkovi?, Toma?,Dol?ak, Ana,Gobec, Stanislav,Mlinari?, Larisa,Ogorevc, Eva,Sova, Matej

, (2021/04/02)

Indoleamine 2,3-dioxygenase 1 (IDO1) is a promising target in immunomodulation of several pathological conditions, especially cancers. Here we present the synthesis of a series of IDO1 inhibitors with the novel isoxazolo[5,4-d]pyrimidin-4(5H)-one scaffold. A focused library was prepared using a 6-or 7-step synthetic procedure to allow a systematic investigation of the structure-activity relationships of the described scaffold. Chemistry-driven modifications lead us to the discovery of our best-in-class inhibitors possessing p-trifluoromethyl (23), p-cyclohexyl (32), or p-methoxycarbonyl (20, 39) substituted aniline moieties with IC50 values in the low micromolar range. In addition to hIDO1, compounds were tested for their inhibition of indoleamine 2,3-dioxygenase 2 and tryptophan dioxygenase, and found to be selective for hIDO1. Our results thus demon-strate a successful study on IDO1-selective isoxazolo[5,4-d]pyrimidin-4(5H)-one inhibitors, defining promising chemical probes with a novel scaffold for further development of potent small-molecule immunomodulators.

Quinazoline derivative and application thereof as antitumor drug

-

Paragraph 0073-0076, (2020/08/22)

The invention belongs to the technical field of medicinal chemistry, and relates to a quinazoline derivative shown as a general formula (I), physiologically acceptable salt formed by the quinazoline derivative and inorganic or organic acid, a pharmaceutical composition containing the quinazoline derivative and the physiologically acceptable salt, and application of the quinazoline derivative and the pharmaceutical composition to preparation of drugs for treating tumor diseases, particularly drugs for treating abnormal EGFR family diseases. The compound has pharmacological properties with important values, and especially has an inhibition effect on signal transduction caused by tyrosine kinase.

DRUGS TO TREAT OCULAR DISORDERS

-

Page/Page column 223, (2019/11/12)

The present invention provides new prodrugs of therapeutically active loop diuretics, including oligomeric prodrugs, and compositions to treat medical disorders, for example, ocular disorders such as glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

Design and synthesis of aminothiazolyl norfloxacin analogues as potential antimicrobial agents and their biological evaluation

Wang, Liang-Liang,Battini, Narsaiah,Bheemanaboina, Rammohan R.Yadav,Zhang, Shao-Lin,Zhou, Cheng-He

, p. 105 - 123 (2019/02/15)

A series of aminothiazolyl norfloxacin analogues as a new type of potential antimicrobial agents were synthesized and screened for their antimicrobial activities. Most of the prepared compounds exhibited excellent inhibitory efficiencies. Especially, norfloxacin analogue II-c displayed superior antimicrobial activities against K. pneumoniae and C. albicans with MIC values of 0.005 and 0.010 mM to reference drugs, respectively. This compound not only showed broad antimicrobial spectrum, rapid bactericidal efficacy and strong enzymes inhibitory potency including DNA gyrase and chitin synthase (CHS), low toxicity against mammalian cells and no obvious propensity to trigger the development of bacterial resistance, but also exerted efficient membrane permeability, and could effectively intercalate into K. pneumoniae DNA to form a steady supramolecular complex, which might block DNA replication to exhibit their powerful antimicrobial activity. Quantum chemical studies were also performed to explain the high antimicrobial activities. Molecular docking showed that compound II-c could bind with gyrase–DNA and topoisomerase IV–DNA through hydrogen bonds and π-π stacking.

Design and Synthesis of New Aryloxy-linked Dimeric 1,2,3-Triazoles via Click Chemistry Approach: Biological Evaluation and Molecular Docking Study

Deshmukh, Tejshri R.,Khare, Smita P.,Krishna, Vagolu S.,Sriram, Dharmarajan,Sangshetti, Jaiprakash N.,Bhusnure, Omprakash,Khedkar, Vijay M.,Shingate, Bapurao B.

, p. 2144 - 2162 (2019/07/12)

A quest for more potent new antitubercular agents has prompted to design and synthesize aryloxy-linked dimeric 1,2,3-triazoles (4a–j), from azides (2a-e) and bis(prop-2-yn-1-yloxy)benzene (3a–b) on 1,3-dipolar cycloaddition reaction via copper (I)-catalyzed click chemistry approach with good to better yields. The titled compounds (4a–j) were designed using molecular hybridization approach by assembling various bioactive pharmacophoric fragments in a single molecular framework. All the synthesized compounds have been screened for their in vitro antitubercular, antifungal, and antioxidant activities against their respective strains. Among them, 4h and 4i show the highest antifungal activity, whereas compounds 4h, 4i, and 4j have revealed promising antitubercular activity against their respective strains. In addition to this, most of the synthesized compounds were found as potent antifungal and antioxidant agents. A significant network of bonded and non-bonded interactions stabilized these molecules into the active site of fungal CYP51 that is realized from the obtained well-placed docking poses and the associated thermodynamic interactions with the enzyme. The synthesized compounds have also been analyzed for absorption, distribution, metabolism, and excretion properties.

Synthesis, bioevaluation and molecular docking study of new piperazine and amide linked dimeric 1,2,3-triazoles

Deshmukh, Tejshri R.,Khare, Smita P.,Khedkar, Vijay M.,Krishna, Vagolu S.,Sangshetti, Jaiprakash N.,Shingate, Bapurao B.,Sriram, Dharmarajan

supporting information, (2019/12/03)

In search of more potent new antitubercular agents, a library of novel piperazine tethered dimeric 1,2,3-triazoles were designed by assembling 1,2,3-triazoles and piperazine in a single molecular architectural framework. The titled compounds (3a–m) were synthesized by 1,3-dipolar cycloaddition of 1,4-di(prop-2-yn-1-yl)piperazine (1) and various azides (2a–m) using click chemistry approach with good yields. All the synthesized compounds (3a–m) have been screened for their in vitro antitubercular, antifungal and antioxidant activities against their respective strains. Among them, 3b, 3d, and 3i have revealed promising antitubercular activity against Mycobacterium tuberculosis (Mtb) H37Rv with MIC 12.5 μg/mL. Molecular docking results provided well-clustered solutions to the mode of binding for these molecules into the active site of Mtb enoyl reductase (InhA). In addition to this, most of synthesized compounds were found to have potential antifungal as well as antioxidant activity.

Design, synthesis and evaluation of new indolylpyrimidylpiperazines for gastrointestinal cancer therapy

Tan, Aaron,Babak, Maria V.,Venkatesan, Gopalakrishnan,Lim, Clarissa,Klotz, Karl-Norbert,Herr, Deron Raymond,Cheong, Siew Lee,Federico, Stephanie,Spalluto, Giampiero,Ong, Wei-Yi,Chen, Yu Zong,Loo, Jason Siau Ee,Pastori, Giorgia

, (2019/11/02)

Human A3 adenosine receptor hA3AR has been implicated in gastrointestinal cancer, where its cellular expression has been found increased, thus suggesting its potential as a molecular target for novel anticancer compounds. Observation

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 2675-89-0